Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
- PMID: 17559344
- DOI: 10.2217/14622416.8.6.547
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Abstract
Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes.
Materials & methods: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 microM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation.
Results: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's r(S) = 0.54; p < 0.0001) and bupropion hydroxylase activity (r(S) = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/*6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation.
Conclusions: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.
Similar articles
-
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Drug Metab Dispos. 2012 Apr;40(4):717-25. doi: 10.1124/dmd.111.042416. Epub 2012 Jan 9. Drug Metab Dispos. 2012. PMID: 22232427 Free PMC article.
-
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. doi: 10.1124/jpet.103.049601. Epub 2003 Apr 3. J Pharmacol Exp Ther. 2003. PMID: 12676886
-
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.Drug Metab Dispos. 2010 Jul;38(7):1218-29. doi: 10.1124/dmd.109.031393. Epub 2010 Mar 24. Drug Metab Dispos. 2010. PMID: 20335270 Free PMC article.
-
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.Drug Metab Dispos. 2019 Oct;47(10):1195-1205. doi: 10.1124/dmd.119.086348. Epub 2019 Jul 19. Drug Metab Dispos. 2019. PMID: 31324697 Free PMC article. Review.
-
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.Curr Drug Metab. 2009 Sep;10(7):730-53. doi: 10.2174/138920009789895534. Curr Drug Metab. 2009. PMID: 19702527 Review.
Cited by
-
Bioactivation of chlorpyrifos by CYP2B6 variants.Xenobiotica. 2012 Dec;42(12):1255-62. doi: 10.3109/00498254.2012.702246. Epub 2012 Jul 10. Xenobiotica. 2012. PMID: 22775490 Free PMC article.
-
Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.Pharmgenomics Pers Med. 2021 Mar 16;14:335-347. doi: 10.2147/PGPM.S289471. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33758532 Free PMC article.
-
A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment.Biomolecules. 2024 Jan 12;14(1):99. doi: 10.3390/biom14010099. Biomolecules. 2024. PMID: 38254699 Free PMC article. Review.
-
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Eur J Clin Pharmacol. 2014 Apr;70(4):379-89. doi: 10.1007/s00228-013-1634-1. Epub 2014 Jan 5. Eur J Clin Pharmacol. 2014. PMID: 24390631 Review.
-
In vitro Assessment of the Effects of Silybin on CYP2B6-mediated Metabolism.Planta Med. 2023 Oct;89(13):1195-1203. doi: 10.1055/a-2102-0648. Epub 2023 May 26. Planta Med. 2023. PMID: 37236224 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases